Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS
- Copycats of best-seller might be delayed through December 2027
- Lawsuits were filed after Novartis won patent case last week
This article is for subscribers only.
Novartis AG has launched legal attacks on about two dozen generic-drug makers in a move to protect U.S. sales of its best-selling branded drug.
The lawsuits, filed in federal court in Wilmington, Delaware, come just days after Novartis won a patent case last week that had challenged the originality of a patent on Novartis’s Gilenya drug, used for treating multiple sclerosis.